Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy for Pediatirc Relapsed and Refractory Acute Lymphoblastic Leukemia Followed By TCR Αβ-Depleted Haplo-HSCT | Synapse
March 3, 2026
Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy for Pediatirc Relapsed and Refractory Acute Lymphoblastic Leukemia Followed By TCR Αβ-Depleted Haplo-HSCT
Puntos clave
MRD negativity before transplant is associated with improved outcomes after CAR-T therapy for pediatric acute lymphoblastic leukemia.
Children achieving MRD negativity had better survival rates, indicating the importance of early response to treatment.
This analysis includes pediatric patients undergoing CAR-T therapy followed by TCR αβ-depleted haplo-HSCT, emphasizing management strategies.
Results highlight the need for incorporating MRD status in treatment planning, potentially improving patient prognoses.